Le Lézard
Classified in: Health
Subject: ACC

Annual General Meeting in Cantargia AB (publ)


STOCKHOLM, May 23, 2022 /PRNewswire/ -- Cantargia's Annual General Meeting on 23 May 2022 resolved in accordance with the following:

That no dividend would be paid.

For further information, please contact

Göran Forsberg, CEO

Telephone: +46 (0)46-275 62 60

E-mail: goran.forsberg@cantargia.com

About Cantargia

Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The lead project, the antibody nadunolimab (CAN04), is being studied clinically in combination with chemotherapy or immune therapy in a series of clinical studies - CANFOUR, CIRIFOUR, CAPAFOUR, CESTAFOUR and TRIFOUR - with a primary focus on non-small cell lung cancer and pancreatic cancer. Positive interim data from the combination with chemotherapy indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second project, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at https://cantargia.com/en/.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/cantargia-ab/r/annual-general-meeting-in-cantargia-ab--publ-,c3572792

The following files are available for download:

https://mb.cision.com/Main/7470/3572792/1583594.pdf

Kommuniké AGM 2022 PR En 220523


These press releases may also interest you

2 jui 2022
Maryland University of Integrative Health (MUIH) will begin offering its...

2 jui 2022
Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced positive data from its EfficAPSI real-world study. Presented at the 2022 European Academy of Allergy and Clinical Immunology (EAACI)...

2 jui 2022
Seagen Inc. today announced full results from the pivotal phase 2 MOUNTAINEER trial, which showed TUKYSA® (tucatinib) in combination with trastuzumab was well-tolerated with durable responses in patients with previously treated HER2-positive...

2 jui 2022
Northern Utah Rehabilitation Hospital (NURH),nationally recognized as a healthcare leader for rehabilitative care for six years in a row (2015 to 2020), is proud to hold a Neuro Day event on July 7th, 2022, from 11 am to 2 pm to showcase the latest...

1 jui 2022
Product photos are available: https://recalls-rappels.canada.ca/en/alert-recall/twa-fungi-brand-king-oyster-mushroom-recalled-due-listeria-monocytogenes Summary Brand(s): TWA FungiProduct: King Oyster MushroomCompanies: Kam Ding Investment Ltd.Issue:...

1 jui 2022
Nutricosmetics Market Facts at a Glance- Companies: 10+ ? Including ActivInside, Borba LLC, Functionalab, Herbalife Nutrition Ltd.,...



News published on 23 may 2022 at 12:04 and distributed by: